<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619536</url>
  </required_header>
  <id_info>
    <org_study_id>CD388.SQ.1.03</org_study_id>
    <nct_id>NCT05619536</nct_id>
  </id_info>
  <brief_title>Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD388 Subcutaneous Administration in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cidara Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cidara Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability profile of CD388&#xD;
      Injection, as compared to saline placebo, when dosed by subcutaneous (SQ) administration as a&#xD;
      single dose to healthy Japanese adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, single-center, prospective, randomized, double-blind study of ascending&#xD;
      single doses of CD388 Injection administered SQ to healthy Japanese adult subjects. The goals&#xD;
      are to assess safety, tolerability, and pharmacokinetics (PK) of CD388.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 18, 2022</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) after a Single Dose of CD388</measure>
    <time_frame>From Day 1 through the final study visit (Day 120 for Cohort 1; Day 165 for Cohorts 2 and 3)</time_frame>
    <description>Number of subjects with incidences of TEAEs, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) Following CD388 Injection Administration</measure>
    <time_frame>At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)</time_frame>
    <description>Evaluation of the maximum plasma concentration (Cmax) following a single dose of CD388.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) Following CD388 Injection Administration</measure>
    <time_frame>At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)</time_frame>
    <description>Evaluation of the time to maximum plasma concentration (Tmax) following a single dose of CD388.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t½) Following CD388 Injection Administration</measure>
    <time_frame>At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)</time_frame>
    <description>Evaluation of the terminal elimination half-life (t½) following a single dose of CD388.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) Following CD388 Injection Administration</measure>
    <time_frame>At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)</time_frame>
    <description>Evaluation of the apparent clearance (CL/F) following a single dose of CD388.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (VZ/F) Following CD388 Injection Administration</measure>
    <time_frame>At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)</time_frame>
    <description>Evaluation of the apparent volume of distribution (VZ/F) following a single dose of CD388.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following CD388 Injection Administration</measure>
    <time_frame>At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)</time_frame>
    <description>Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC0-t) following a single dose of CD388.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC[0-∞]) Following CD388 Injection Administration</measure>
    <time_frame>At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)</time_frame>
    <description>Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞) following a single dose of CD388.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 subjects randomized in a 7:2 ratio to receive either 50 mg CD388 SQ injection or matching placebo injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 subjects randomized in a 7:2 ratio to receive either 150 mg CD388 SQ injection or matching placebo injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 subjects randomized in a 7:2 ratio to receive either 450 mg CD388 SQ injection or matching placebo injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>CD388 Injection</intervention_name>
    <description>CD388 liquid for injection</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>Sterile normal saline for injection</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be of Japanese descent with Japanese parents and grandparents, as determined by&#xD;
             subject's verbal report.&#xD;
&#xD;
          2. Willing and able to provide written informed consent.&#xD;
&#xD;
          3. Males and females 18 to 65 years of age, inclusive.&#xD;
&#xD;
          4. A female subject must meet one of the following criteria:&#xD;
&#xD;
               1. If of childbearing potential - agrees to use a highly effective, preferably&#xD;
                  user-independent method of contraception (failure rate of &lt;1 percent per year&#xD;
                  when used consistently and correctly) for at least 30 days prior to screening and&#xD;
                  agrees to remain on a highly effective method until 7 months after last dose of&#xD;
                  study medication, whichever is longer. Examples of highly-effective methods of&#xD;
                  contraception include: abstinence from heterosexual intercourse; hormonal&#xD;
                  contraceptives (birth control pills, injectable/implant/insertable hormonal birth&#xD;
                  control products, transdermal patch); intrauterine device (with or without&#xD;
                  hormones); or a double barrier method (e.g., condom and spermicide).&#xD;
&#xD;
               2. If a female of non-childbearing potential - should be surgically sterile (i.e.,&#xD;
                  has undergone complete hysterectomy, bilateral oophorectomy, or tubal&#xD;
                  ligation/occlusion without reversal surgery) or in a menopausal state (at least 1&#xD;
                  year without menses), as confirmed by follicle-stimulating hormone (FSH) levels&#xD;
                  (≥40 milli-International units [mIU]/milliliter [mL]).&#xD;
&#xD;
          5. A woman of childbearing potential must have a negative highly sensitive serum&#xD;
             pregnancy test (β-human chorionic gonadotropin) at screening and a negative urine&#xD;
             pregnancy test on Day -1 before the first dose of study drug.&#xD;
&#xD;
          6. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted&#xD;
             reproduction during the study and for a period of at least 7 months after study drug&#xD;
             administration.&#xD;
&#xD;
          7. A male subject that engages in sexual activity that has the risk of pregnancy must&#xD;
             agree to use a double barrier method (e.g., condom and spermicide) and agree to not&#xD;
             donate sperm during the study and for at least 7 months after the last dose of the&#xD;
             study medication.&#xD;
&#xD;
          8. Good health and without signs or symptoms of current illness.&#xD;
&#xD;
          9. Normal clinical examination, including:&#xD;
&#xD;
               1. No physical examination findings that an Investigator determines would interfere&#xD;
                  with interpretation of study results.&#xD;
&#xD;
               2. Screening ECG without clinically significant abnormalities.&#xD;
&#xD;
               3. Creatinine clearance (CrCL) ≥80 mL/minute as calculated using the Cockcroft-Gault&#xD;
                  equation.&#xD;
&#xD;
               4. Negative urine screen for drugs of abuse and alcohol at screening and Day -1.&#xD;
&#xD;
         10. Body weight ≥50 kilograms (kg) and body mass index (BMI; calculated as weight in kg&#xD;
             divided by height in meters [m] squared) between 18.0 and 30.0 kg/m^2, inclusive.&#xD;
&#xD;
         11. Willing to refrain from strenuous physical activity that could cause muscle aches or&#xD;
             injury, including contact sports, at any time from screening through 30 days after any&#xD;
             dose of study drug.&#xD;
&#xD;
         12. Subject has adequate venous access for blood collection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any hypersensitivity or allergic reaction to zanamivir or other&#xD;
             neuraminidase inhibitors (i.e., laninamivir, oseltamivir, peramivir), or to excipients&#xD;
             of the CD388 Injection drug formulation; or history of drug-induced exfoliative skin&#xD;
             disorders (e.g., Stevens-Johnson syndrome [SJS], erythema multiforme, or toxic&#xD;
             epidermal necrolysis [TEN]).&#xD;
&#xD;
          2. History of any of the following:&#xD;
&#xD;
               1. Allergies, anaphylaxis, skin rashes (foods such as milk, eggs, medications,&#xD;
                  vaccines, polyethylene glycol [PEG], etc.).&#xD;
&#xD;
               2. Chronic immune-mediated disease, positive first-degree family history of&#xD;
                  autoimmune diseases.&#xD;
&#xD;
               3. Atopic dermatitis or psoriasis.&#xD;
&#xD;
               4. Bleeding disorder.&#xD;
&#xD;
               5. Psychiatric condition, seizures, hallucinations, anxiety, depression, or&#xD;
                  treatment for mental conditions.&#xD;
&#xD;
               6. Migraines.&#xD;
&#xD;
               7. Syncope, or vasovagal syndrome with injections or blood draws.&#xD;
&#xD;
               8. Cardiac arrhythmia considered clinically significant by the Investigator.&#xD;
&#xD;
          3. Subjects with one or more of the following laboratory abnormalities at screening as&#xD;
             defined by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and&#xD;
             Pediatric Adverse Events v2.1 (DAIDS 2017):&#xD;
&#xD;
               1. Serum creatinine, Grade ≥1 (≥1.1 × upper limit of normal [ULN]).&#xD;
&#xD;
               2. Pancreatic amylase or lipase, Grade ≥2 (≥1.5 × ULN).&#xD;
&#xD;
               3. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT), Grade ≥1&#xD;
                  (≥1.25 × ULN).&#xD;
&#xD;
               4. Total bilirubin, Grade ≥1 (≥1.1 × ULN).&#xD;
&#xD;
               5. Any other toxicity Grade ≥2, except for Grade 2 elevations of triglycerides, low&#xD;
                  density lipoprotein cholesterol, and/or total cholesterol.&#xD;
&#xD;
               6. Any other laboratory abnormality considered to be clinically significant by the&#xD;
                  Investigator.&#xD;
&#xD;
                    -  Note: Retesting of abnormal laboratory values that may lead to exclusion&#xD;
                       will be allowed once without prior asking approval from the Sponsor.&#xD;
                       Retesting will take place during a scheduled or unscheduled visit during&#xD;
                       screening. Subjects with a normal value at retest may be included.&#xD;
&#xD;
          4. Alcohol or drug addiction in the past 2 years.&#xD;
&#xD;
          5. Experiencing symptoms of acute illness or chronic disease within 14 days prior to&#xD;
             clinical research unit (CRU) check-in.&#xD;
&#xD;
          6. At screening, a positive result for hepatitis B virus surface antigen, hepatitis C&#xD;
             virus antibody, or human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          7. A positive result at CRU check-in for severe acute respiratory syndrome coronavirus 2&#xD;
             (SARS-CoV-2) by polymerase chain reaction (PCR).&#xD;
&#xD;
          8. Unwilling to comply with local health policy effective at the time regarding&#xD;
             coronavirus disease 2019 (COVID-19). Full COVID-19 vaccination prior to participation&#xD;
             is strongly recommended.&#xD;
&#xD;
          9. Women who are pregnant or nursing.&#xD;
&#xD;
         10. Received any over-the-counter (OTC) medications or nutritional supplements within 7&#xD;
             days, or any prescription medications within 14 days or &lt;5 half-lives prior to dosing,&#xD;
             whichever is longest (except for hormonal contraceptives, acetaminophen, or&#xD;
             ibuprofen).&#xD;
&#xD;
         11. Current nicotine user or has quit habitual nicotine use in the 30 days prior to&#xD;
             screening.&#xD;
&#xD;
         12. Received any vaccines or immunoglobulins within 28 days prior to dosing (90 days in&#xD;
             case of intravenous immunoglobulin [IVIg] or biologics, or 14 days for COVID-19&#xD;
             vaccine).&#xD;
&#xD;
         13. Donated blood (within 56 days of screening) or plasma (within 7 days of screening) or&#xD;
             experienced significant blood loss or significant blood draw (blood donation or blood&#xD;
             loss ≥500 mL) when participating in non-interventional clinical trials within 30 days&#xD;
             prior to dosing.&#xD;
&#xD;
         14. Received a blood transfusion within 28 days prior to dosing.&#xD;
&#xD;
         15. Received any biologics within 90 days prior to dosing; or previous participation in&#xD;
             another study (including investigational device studies) within 30 days of dosing or 5&#xD;
             half-lives of the study drug, whichever is longer, prior to screening (prior&#xD;
             participation at any time in non-invasive methodology trials in which no drugs were&#xD;
             given is acceptable).&#xD;
&#xD;
         16. Previous treatment with CD388.&#xD;
&#xD;
         17. Preplanned surgery at any time during the study.&#xD;
&#xD;
         18. The Principal Investigator (PI) considers that the volunteer should not participate in&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ozlem Equils, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cidara Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youngjun Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altasciences Clinical Los Angeles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altasciences Clinical Los Angeles, Inc.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>May 2, 2023</last_update_submitted>
  <last_update_submitted_qc>May 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

